ReviewDrugs & aging2016
Therapeutic Potential of Antidiabetic Medications in the Treatment of Cognitive Dysfunction and Dementia.
Review in Drugs & aging, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 17 citations in OpenAlex.
- Insulin use in diabetes association with cognitive impairment and dementia incidence.BMC pharmacology & toxicology · 2025Article
- Association between exenatide use and incidence of Alzheimer's disease.Alzheimer's & dementia (New York, N. Y.) · 2021Article
- Relationships between Cognitive Function and Odor Identification, Balance Capability, and Muscle Strength in Middle-Aged Persons with and without Type 2 Diabetes.Journal of diabetes research · 2021Article
- Article
- Regulation of Diabetes: a Therapeutic Strategy for Alzheimer's Disease?Journal of Korean medical science · 2019Review
- Lipoprotein-associated Phospholipase A2 Is Associated with Risk of Mild Cognitive Impairment in Chinese Patients with Type 2 Diabetes.Scientific reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It has been established that diabetes mellitus (DM) is a risk factor for dementia, and recent studies have clearly shown that dementia is one of the complications of DM. The increase of cognitively impaired subjects with the progression of aging in the population is an urgent worldwide issue. Due to the pharmacological advancement in the field of DM, we now have many kinds of antidiabetic medications with a wide variety of mechanisms of action and characteristics. It is a good time to review the characteristics of each antidiabetic medication and the evidence related to their prevention of cognitive dysfunction or preservation of cognition. The available data on the effects of antidiabetics on cognitive dysfunction and dementia show that several of the antidiabetics have the potential to improve cognition. The accumulation of more data to determine the best ways to use antidiabetics in order to prevent cognitive impairment would be warranted. To this end, the present review will try to illustrate the horizon of achievement in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.